{"id":1143,"date":"2014-01-22T15:19:56","date_gmt":"2014-01-22T15:19:56","guid":{"rendered":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?p=1143"},"modified":"2014-01-27T17:41:38","modified_gmt":"2014-01-27T17:41:38","slug":"nichtsteroidale-antiphlogistika-kardiovaskulaere-risiken-beachten","status":"publish","type":"post","link":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/nichtsteroidale-antiphlogistika-kardiovaskulaere-risiken-beachten\/","title":{"rendered":"Nichtsteroidale Antiphlogistika: kardiovaskul\u00e4re Risiken beachten!"},"content":{"rendered":"<p>AMB 2013,\u00a047, 46a &nbsp; Nichtsteroidale Antiphlogistika: kardiovaskul\u00e4re Risiken beachten! &nbsp; Fazit: Die Daten mehren sich, dass das oft verordnete nichtsteroidale Antiphlogistikum Diclofenac das Risiko f\u00fcr kardiovaskul\u00e4re Ereignisse in \u00e4hnlichem Ausma\u00df erh\u00f6ht wie das 2004 aus diesem Grund vom Markt genommene Rofecoxib. Risikobewertungsverfahren zur Kl\u00e4rung dieses Verdachts &#8230;\u00a0Bitte abonnieren oder Kennlernartikel anfordern &#8211;&gt; &nbsp; Schlagworte zum [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>AMB 2013,\u00a047, 46a &nbsp; Nichtsteroidale Antiphlogistika: kardiovaskul\u00e4re Risiken beachten! &nbsp; Fazit: Die Daten mehren sich, dass das oft verordnete nichtsteroidale Antiphlogistikum Diclofenac das Risiko f\u00fcr kardiovaskul\u00e4re Ereignisse in \u00e4hnlichem Ausma\u00df erh\u00f6ht wie das 2004 aus diesem Grund vom Markt genommene Rofecoxib. Risikobewertungsverfahren zur Kl\u00e4rung dieses Verdachts &#8230;\u00a0Bitte abonnieren oder Kennlernartikel anfordern &#8211;&gt; &nbsp; Schlagworte zum [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","footnotes":""},"categories":[24,30],"tags":[438,48,49,50,51,52,53,54],"class_list":["post-1143","post","type-post","status-publish","format-standard","hentry","category-jahr-2013-band-47","category-monat-06","tag-celecoxib","tag-cox-2-hemmer","tag-coxibe","tag-diclofenac","tag-ibuprofen","tag-naproxen","tag-nichtsteroidale-antiphlogistika","tag-nsaid"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nichtsteroidale Antiphlogistika: kardiovaskul\u00e4re Risiken beachten!<\/title>\n<meta name=\"description\" content=\"Fazit: Die Daten mehren sich, dass das oft verordnete nichtsteroidale Antiphlogistikum Diclofenac das Risiko f\u00fcr kardiovaskul\u00e4re Ereignisse in \u00e4hnlichem Ausma\u00df erh\u00f6ht wie das 2004 aus diesem Grund vom Markt genommene Rofecoxib. Risikobewertungsverfahren ...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/nichtsteroidale-antiphlogistika-kardiovaskulaere-risiken-beachten\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nichtsteroidale Antiphlogistika: kardiovaskul\u00e4re Risiken beachten!\" \/>\n<meta property=\"og:description\" content=\"Fazit: Die Daten mehren sich, dass das oft verordnete nichtsteroidale Antiphlogistikum Diclofenac das Risiko f\u00fcr kardiovaskul\u00e4re Ereignisse in \u00e4hnlichem Ausma\u00df erh\u00f6ht wie das 2004 aus diesem Grund vom Markt genommene Rofecoxib. Risikobewertungsverfahren ...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/nichtsteroidale-antiphlogistika-kardiovaskulaere-risiken-beachten\/\" \/>\n<meta property=\"og:site_name\" content=\"Der Arzneimittelbrief\" \/>\n<meta property=\"article:publisher\" content=\"http:\/\/www.facebook.com\/derarzneimittelbrief.de\" \/>\n<meta property=\"article:published_time\" content=\"2014-01-22T15:19:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2014-01-27T17:41:38+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg\" \/>\n<meta name=\"author\" content=\"henk-amb\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"henk-amb\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"1\u00a0Minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/nichtsteroidale-antiphlogistika-kardiovaskulaere-risiken-beachten\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/nichtsteroidale-antiphlogistika-kardiovaskulaere-risiken-beachten\\\/\"},\"author\":{\"name\":\"henk-amb\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\"},\"headline\":\"Nichtsteroidale Antiphlogistika: kardiovaskul\u00e4re Risiken beachten!\",\"datePublished\":\"2014-01-22T15:19:56+00:00\",\"dateModified\":\"2014-01-27T17:41:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/nichtsteroidale-antiphlogistika-kardiovaskulaere-risiken-beachten\\\/\"},\"wordCount\":223,\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/nichtsteroidale-antiphlogistika-kardiovaskulaere-risiken-beachten\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\",\"keywords\":[\"Celecoxib\",\"COX-2-Hemmer\",\"Coxibe\",\"Diclofenac\",\"Ibuprofen\",\"Naproxen\",\"Nichtsteroidale Antiphlogistika\",\"NSAID\"],\"articleSection\":[\"Jahr 2013 Band 47\",\"Monat 06\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/nichtsteroidale-antiphlogistika-kardiovaskulaere-risiken-beachten\\\/\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/nichtsteroidale-antiphlogistika-kardiovaskulaere-risiken-beachten\\\/\",\"name\":\"Nichtsteroidale Antiphlogistika: kardiovaskul\u00e4re Risiken beachten!\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/nichtsteroidale-antiphlogistika-kardiovaskulaere-risiken-beachten\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/nichtsteroidale-antiphlogistika-kardiovaskulaere-risiken-beachten\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\",\"datePublished\":\"2014-01-22T15:19:56+00:00\",\"dateModified\":\"2014-01-27T17:41:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\"},\"description\":\"Fazit: Die Daten mehren sich, dass das oft verordnete nichtsteroidale Antiphlogistikum Diclofenac das Risiko f\u00fcr kardiovaskul\u00e4re Ereignisse in \u00e4hnlichem Ausma\u00df erh\u00f6ht wie das 2004 aus diesem Grund vom Markt genommene Rofecoxib. Risikobewertungsverfahren ...\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/nichtsteroidale-antiphlogistika-kardiovaskulaere-risiken-beachten\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/nichtsteroidale-antiphlogistika-kardiovaskulaere-risiken-beachten\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/nichtsteroidale-antiphlogistika-kardiovaskulaere-risiken-beachten\\\/#primaryimage\",\"url\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\",\"contentUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/nichtsteroidale-antiphlogistika-kardiovaskulaere-risiken-beachten\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nichtsteroidale Antiphlogistika: kardiovaskul\u00e4re Risiken beachten!\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\",\"name\":\"Der Arzneimittelbrief\",\"description\":\"Unabh\u00e4ngige Arzneimittelinformationen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\",\"name\":\"henk-amb\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"caption\":\"henk-amb\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nichtsteroidale Antiphlogistika: kardiovaskul\u00e4re Risiken beachten!","description":"Fazit: Die Daten mehren sich, dass das oft verordnete nichtsteroidale Antiphlogistikum Diclofenac das Risiko f\u00fcr kardiovaskul\u00e4re Ereignisse in \u00e4hnlichem Ausma\u00df erh\u00f6ht wie das 2004 aus diesem Grund vom Markt genommene Rofecoxib. Risikobewertungsverfahren ...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/nichtsteroidale-antiphlogistika-kardiovaskulaere-risiken-beachten\/","og_locale":"de_DE","og_type":"article","og_title":"Nichtsteroidale Antiphlogistika: kardiovaskul\u00e4re Risiken beachten!","og_description":"Fazit: Die Daten mehren sich, dass das oft verordnete nichtsteroidale Antiphlogistikum Diclofenac das Risiko f\u00fcr kardiovaskul\u00e4re Ereignisse in \u00e4hnlichem Ausma\u00df erh\u00f6ht wie das 2004 aus diesem Grund vom Markt genommene Rofecoxib. Risikobewertungsverfahren ...","og_url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/nichtsteroidale-antiphlogistika-kardiovaskulaere-risiken-beachten\/","og_site_name":"Der Arzneimittelbrief","article_publisher":"http:\/\/www.facebook.com\/derarzneimittelbrief.de","article_published_time":"2014-01-22T15:19:56+00:00","article_modified_time":"2014-01-27T17:41:38+00:00","og_image":[{"url":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","type":"","width":"","height":""}],"author":"henk-amb","twitter_misc":{"Verfasst von":"henk-amb","Gesch\u00e4tzte Lesezeit":"1\u00a0Minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/nichtsteroidale-antiphlogistika-kardiovaskulaere-risiken-beachten\/#article","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/nichtsteroidale-antiphlogistika-kardiovaskulaere-risiken-beachten\/"},"author":{"name":"henk-amb","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937"},"headline":"Nichtsteroidale Antiphlogistika: kardiovaskul\u00e4re Risiken beachten!","datePublished":"2014-01-22T15:19:56+00:00","dateModified":"2014-01-27T17:41:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/nichtsteroidale-antiphlogistika-kardiovaskulaere-risiken-beachten\/"},"wordCount":223,"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/nichtsteroidale-antiphlogistika-kardiovaskulaere-risiken-beachten\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","keywords":["Celecoxib","COX-2-Hemmer","Coxibe","Diclofenac","Ibuprofen","Naproxen","Nichtsteroidale Antiphlogistika","NSAID"],"articleSection":["Jahr 2013 Band 47","Monat 06"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/nichtsteroidale-antiphlogistika-kardiovaskulaere-risiken-beachten\/","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/nichtsteroidale-antiphlogistika-kardiovaskulaere-risiken-beachten\/","name":"Nichtsteroidale Antiphlogistika: kardiovaskul\u00e4re Risiken beachten!","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/nichtsteroidale-antiphlogistika-kardiovaskulaere-risiken-beachten\/#primaryimage"},"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/nichtsteroidale-antiphlogistika-kardiovaskulaere-risiken-beachten\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","datePublished":"2014-01-22T15:19:56+00:00","dateModified":"2014-01-27T17:41:38+00:00","author":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937"},"description":"Fazit: Die Daten mehren sich, dass das oft verordnete nichtsteroidale Antiphlogistikum Diclofenac das Risiko f\u00fcr kardiovaskul\u00e4re Ereignisse in \u00e4hnlichem Ausma\u00df erh\u00f6ht wie das 2004 aus diesem Grund vom Markt genommene Rofecoxib. Risikobewertungsverfahren ...","breadcrumb":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/nichtsteroidale-antiphlogistika-kardiovaskulaere-risiken-beachten\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/nichtsteroidale-antiphlogistika-kardiovaskulaere-risiken-beachten\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/nichtsteroidale-antiphlogistika-kardiovaskulaere-risiken-beachten\/#primaryimage","url":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","contentUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/nichtsteroidale-antiphlogistika-kardiovaskulaere-risiken-beachten\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/"},{"@type":"ListItem","position":2,"name":"Nichtsteroidale Antiphlogistika: kardiovaskul\u00e4re Risiken beachten!"}]},{"@type":"WebSite","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/","name":"Der Arzneimittelbrief","description":"Unabh\u00e4ngige Arzneimittelinformationen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937","name":"henk-amb","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","caption":"henk-amb"}}]}},"_links":{"self":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/1143","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/comments?post=1143"}],"version-history":[{"count":2,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/1143\/revisions"}],"predecessor-version":[{"id":1202,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/1143\/revisions\/1202"}],"wp:attachment":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/media?parent=1143"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/categories?post=1143"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/tags?post=1143"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}